BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 20920292)

  • 21. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions.
    Bracken AP; Dietrich N; Pasini D; Hansen KH; Helin K
    Genes Dev; 2006 May; 20(9):1123-36. PubMed ID: 16618801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polycomb group genes are targets of aberrant DNA methylation in renal cell carcinoma.
    Avissar-Whiting M; Koestler DC; Houseman EA; Christensen BC; Kelsey KT; Marsit CJ
    Epigenetics; 2011 Jun; 6(6):703-9. PubMed ID: 21610323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polycomb group protein-associated chromatin is reproduced in post-mitotic G1 phase and is required for S phase progression.
    Aoto T; Saitoh N; Sakamoto Y; Watanabe S; Nakao M
    J Biol Chem; 2008 Jul; 283(27):18905-15. PubMed ID: 18453536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis.
    Smits M; Nilsson J; Mir SE; van der Stoop PM; Hulleman E; Niers JM; de Witt Hamer PC; Marquez VE; Cloos J; Krichevsky AM; Noske DP; Tannous BA; Würdinger T
    Oncotarget; 2010 Dec; 1(8):710-20. PubMed ID: 21321380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma.
    Yonemitsu Y; Imazeki F; Chiba T; Fukai K; Nagai Y; Miyagi S; Arai M; Aoki R; Miyazaki M; Nakatani Y; Iwama A; Yokosuka O
    Hum Pathol; 2009 Sep; 40(9):1304-11. PubMed ID: 19386347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer.
    Pietersen AM; Horlings HM; Hauptmann M; Langerød A; Ajouaou A; Cornelissen-Steijger P; Wessels LF; Jonkers J; van de Vijver MJ; van Lohuizen M
    Breast Cancer Res; 2008; 10(6):R109. PubMed ID: 19099573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer.
    Zeidler M; Kleer CG
    J Mol Histol; 2006 Sep; 37(5-7):219-23. PubMed ID: 16855786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EZH2 is essential for glioblastoma cancer stem cell maintenance.
    Suvà ML; Riggi N; Janiszewska M; Radovanovic I; Provero P; Stehle JC; Baumer K; Le Bitoux MA; Marino D; Cironi L; Marquez VE; Clément V; Stamenkovic I
    Cancer Res; 2009 Dec; 69(24):9211-8. PubMed ID: 19934320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polycomb complex mediated epigenetic reprogramming alters TGF-β signaling via a novel EZH2/miR-490/TGIF2 axis thereby inducing migration and EMT potential in glioblastomas.
    Vinchure OS; Sharma V; Tabasum S; Ghosh S; Singh RP; Sarkar C; Kulshreshtha R
    Int J Cancer; 2019 Sep; 145(5):1254-1269. PubMed ID: 31008529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.
    Orzan F; Pellegatta S; Poliani PL; Pisati F; Caldera V; Menghi F; Kapetis D; Marras C; Schiffer D; Finocchiaro G
    Neuropathol Appl Neurobiol; 2011 Jun; 37(4):381-94. PubMed ID: 20946108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The transcriptional repression by NIPP1 is mediated by Polycomb group proteins.
    Roy N; Van Eynde A; Beke L; Nuytten M; Bollen M
    Biochim Biophys Acta; 2007; 1769(9-10):541-5. PubMed ID: 17804093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer.
    Yu J; Cao Q; Yu J; Wu L; Dallol A; Li J; Chen G; Grasso C; Cao X; Lonigro RJ; Varambally S; Mehra R; Palanisamy N; Wu JY; Latif F; Chinnaiyan AM
    Oncogene; 2010 Sep; 29(39):5370-80. PubMed ID: 20622896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Bmi-1 polycomb protein antagonizes the (-)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival.
    Balasubramanian S; Adhikary G; Eckert RL
    Carcinogenesis; 2010 Mar; 31(3):496-503. PubMed ID: 20015867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of hPHF1 in H3K27 methylation and Hox gene silencing.
    Cao R; Wang H; He J; Erdjument-Bromage H; Tempst P; Zhang Y
    Mol Cell Biol; 2008 Mar; 28(5):1862-72. PubMed ID: 18086877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ezh2 requires PHF1 to efficiently catalyze H3 lysine 27 trimethylation in vivo.
    Sarma K; Margueron R; Ivanov A; Pirrotta V; Reinberg D
    Mol Cell Biol; 2008 Apr; 28(8):2718-31. PubMed ID: 18285464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The polycomb group protein EED interacts with YY1, and both proteins induce neural tissue in Xenopus embryos.
    Satijn DP; Hamer KM; den Blaauwen J; Otte AP
    Mol Cell Biol; 2001 Feb; 21(4):1360-9. PubMed ID: 11158321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overexpression of enhancer of zeste human homolog 2 (EZH2) gene in human cytomegalovirus positive glioblastoma multiforme tissues.
    Ahani N; Shirkoohi R; Rokouei M; Alipour Eskandani M; Nikravesh A
    Med Oncol; 2014 Nov; 31(11):252. PubMed ID: 25294424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis.
    Breuer RH; Snijders PJ; Smit EF; Sutedja TG; Sewalt RG; Otte AP; van Kemenade FJ; Postmus PE; Meijer CJ; Raaphorst FM
    Neoplasia; 2004; 6(6):736-43. PubMed ID: 15720799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression.
    Zheng S; Houseman EA; Morrison Z; Wrensch MR; Patoka JS; Ramos C; Haas-Kogan DA; McBride S; Marsit CJ; Christensen BC; Nelson HH; Stokoe D; Wiemels JL; Chang SM; Prados MD; Tihan T; Vandenberg SR; Kelsey KT; Berger MS; Wiencke JK
    Neuro Oncol; 2011 Mar; 13(3):280-9. PubMed ID: 21339190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin.
    Tong ZT; Cai MY; Wang XG; Kong LL; Mai SJ; Liu YH; Zhang HB; Liao YJ; Zheng F; Zhu W; Liu TH; Bian XW; Guan XY; Lin MC; Zeng MS; Zeng YX; Kung HF; Xie D
    Oncogene; 2012 Feb; 31(5):583-94. PubMed ID: 21685935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.